In This Issue:
Antitrust | Compliance | Corporate | Data Privacy & Cybersecurity |
Foreign Investment | International Trade
This China Newsletter provides an overview of key Q1 2025 developments in the following areas:
Antitrust
- China Unveils Anti-Monopoly Guidelines for Pharmaceutical Sector
Compliance
- China Formally Finalizes First Anti-Corruption Guidelines for the Health Care and Life Sciences Industry
Corporate
- China Streamlines Company Registration: Key Changes Effective February 2025
Data Privacy & Cybersecurity
- China Issues Personal Information Compliance Audit Rule
- China Issues Regulation for Facial Recognition Technology Applications
- China Issues Measures for Labeling AI-Generated and Synthetic Content
Foreign Investment
- China Publishes 2025 Action Plan for Stabilizing Foreign Investment
International Trade
- China Promulgates Regulations for Implementing Anti-Foreign Sanctions Law